en Radiation Biology Radiation Biology تحقيق بديع Original Research <div style="text-align: justify;"><span style="font-size:10pt"><span style="text-justify:newspaper"><span style="text-kashida-space:50%"><span style="line-height:119%"><span style="font-family:Calibri"><span style="color:black"><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Background</span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-weight:bold"><span style="language:en-US">:</span></span></span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">The study aims to explore the relationship between tumor parameters acquired from Ga-68 PSMA PET/CT and GG system in patients who had prostate cancer. </span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Materials and Methods: </span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">One hundred and fourteen patients diagnosed with prostate cancer and who underwent Ga-68 PSMA PET/CT imaging for staging purposes were enrolled. The imaging was performed using a Siemens Biograph Horizon-3R 16 slice PET/CT device, and the tumor parameters (SUVmax, SUVmean, and Tumor volume) were calculated by an experienced nuclear medicine physician. </span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Results: </span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">There was a correlation between GG with SUVmax (p:0.010; r:0.241) and SUVmean (p:0.06; r:0.258). In redicting high-risk patients, ROC analysis was conducted for SUVmax and SUVmean, resulting in significant cut-off values for both parameters. A cut-off value of 9.8 for SUVmax resulted in a sensitivity of 69% and a specificity of 58%. 5.8 cut-off value for SUVmean resulted in 68% sensitivity&nbsp; and 58% specificity. Tumor volume was found to be a significant predictor for distant metastasis. When a cut-off value of 11.53 cm3 was used for tumor volume, sensitivity was found to be 62% and specificity 56%.</span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US"> Conclusion: </span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">According to the results, correlation between GG with SUVmax and SUVmax was significant. Additionally, SUVmax and SUVmean were significant predictors of high-risk prostate cancer, while TV was a significant predictor of distant metastases. In summary, Ga-68-PSMA PET CT are deemed a beneficial imaging modality for both prognosis assessment and staging in clinical.</span></span></span></span></span></span></span></span></span></div> Ga-68 PSMA PET/CT, prostate cancer, pathological grade grouping. 277 281 http://ijrr.com/browse.php?a_code=A-10-1-1325&slc_lang=en&sid=1 F. Demir drfadimedemir@hotmail.com 7900319475328460031029 7900319475328460031029 Yes Department of Nuclear Medicine, Kayseri Training and Research Hospital, Kayseri, Turkey S. Karaçavuş 7900319475328460031030 7900319475328460031030 No Department of Nuclear Medicine, Kayseri Training and Research Hospital, Kayseri, Turkey H. Gençer 7900319475328460031031 7900319475328460031031 No Department of Nuclear Medicine, Kayseri Training and Research Hospital, Kayseri, Turkey A. Özdal 7900319475328460031032 7900319475328460031032 No Department of Nuclear Medicine, Kayseri Training and Research Hospital, Kayseri, Turkey Z. Erdoğan 7900319475328460031033 7900319475328460031033 No Department of Nuclear Medicine, Kayseri Training and Research Hospital, Kayseri, Turkey İ. Çiftçi 7900319475328460031034 7900319475328460031034 No Department of Nuclear Medicine, Kayseri Training and Research Hospital, Kayseri, Turkey F. Çevik Kaya 7900319475328460031035 7900319475328460031035 No Department of Pathology, Kayseri Training and Research Hospital, Kayseri, Turkey N. Özhan 7900319475328460031036 7900319475328460031036 No Department of Oncology, Kayseri Training and Research Hospital, Kayseri, Turkey H. İşçi 7900319475328460031037 7900319475328460031037 No Department of Nuclear Medicine, Kayseri Training and Research Hospital, Kayseri, Turkey M. Kaya 7900319475328460031038 7900319475328460031038 No Department of Nuclear Medicine, Kayseri Training and Research Hospital, Kayseri, Turkey